NRX制药将结合现有临床试验数据与Osmind拟议真实世界数据 申请NRX-100获批

美股速递
Feb 17

NRX制药公司宣布,计划整合其掌握的临床试验数据与Osmind平台提供的拟议真实世界证据,共同向监管机构提交NRX-100的上市申请。这一策略旨在通过传统研究数据与真实临床实践数据的互补,强化该药物治疗方案的论证基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10